Capricor Therapeutics (CAPR) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Wall St futures steady with focus on Mideast talks, US-China summit
- Activist Jana Partners calls for Six Flags sale - WSJ
- Oil holds near two-week lows while diesel cracks hit record peak
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 14, 2023 4:05 PM EST-Completed Targeted Enrollment for HOPE-3, the Phase 3 Trial of CAP-1002 in Duchenne Muscular Dystrophy-
-On Track to Report Interim Futility Analysis in Fourth Quarter of 2023; Successful Outcome Would Trigger Milestone Payment to Capricor Under Commercialization and Distribution Deal with Nippon Shinyaku-
-Positive FDA Feedback on the Proposed Key Clinical and Regulatory Requirements Confirms CAP-1002s Path Towards a Biologics License Application Submission-
-Conference Call and Webcast Today at 4:30 p.m. ET-
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) --... More
